Research
Hormonal
GLP-1 analogs and SGLT-2 inhibitors are promising therapeutic modalities for the obese-diabetic phenotype of HFpEF, with GLP-1 analogs showing significant reduction in epicardial adipose tissue (EAT) and body weight.
Newer diabetes drugs (GLP-1s and SGLT-2 inhibitors) are highly effective for obese HFpEF patients. They help lose weight, reduce heart fat (EAT), and improve heart function. GLP-1s like semaglutide can lead to substantial weight loss (up to 10% or more).
GoodSupportsHIGH confidence
Anti-diabetic agents like glucagon-like-peptide 1 analogs and sodium-glucose co-transporter 2 are promising therapeutic modalities for the obese-diabetic phenotype of heart failure with preserved ejection fraction
Why this rating
Supported by specific trial data cited in the review (e.g., STEP trials, liraglutide studies).
Source
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Aneesh Dhore-Patil et al. · Frontiers in Physiology · 2022
DOI 10.3389/fphys.2021.785879
narrative_reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Visceral Adipose Tissue (VAT) and Epicardial Adipose Tissue (EAT) are stronger predictors of incident HFpEF and mortality than Body Mass Index (BMI) alone.Strong
- Aggressive weight loss via lifestyle modifications or bariatric surgery is the key intervention to reverse adverse left ventricular remodeling and improve outcomes in the obese-diabetic phenotype of heart failure with preserved ejection fraction (HFpEF).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →